Everything below concerns Nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Over 500 mineral blocks are present in Jammu and Kashmir, 261 of which are in the Kashmir Division alone. Kishtwar is known as the 'land of sapphire and saffron'. Resources such as timber, herbs and medicinal shrubs, edibles such as mushroom, chilgoza, black zeera, and saffron are available in the forests. The sapphire reserve mines of Machail, Paddar are a source of mineral wealth. Jammu and Kashmir is the only administrative unit in India with a large amount of borax and sapphire resources. It possesses 36% of the graphite, 21% marble and 14% of gypsum present in India. Coal, limestone and magnesite are found scattered among the different districts of the union territory. Other minerals of significance that occur are bauxite, ball clay and china clay in Udhampur; bentonite in Jammu; diaspore in Rajouri and Udhampur; graphite in Baramulla; lignite and marble in Kupwara; quartz and silica sand in Anantnag, Doda, and Udhampur; and quartzite in Anantnag district. In addition, the Department of Geology and Mining has determined the presence of minerals such as magnetite, dolomite, fuel mineral, decorative building stones, slate, and gemstones. All are materials with commercial and industrial uses in many products and factories. In the fiscal year 2019–20, total exports from Jammu and Kashmir amounted to ₹188.18 million (equivalent to ₹240 million or US$2.5 million in 2026). The Jammu & Kashmir Bank, which is listed as a NIFTY 500 conglomerate, is based in the union territory. Jammu and Kashmir is one of the largest recipients of grants from the central government annually.
2 H2O + SO2Cl2 → 2 HCl + H2SO4 For sulfuryl chloride, this happens at room temperature, but the related sulfuryl fluoride does not hydrolyse at temperatures up to 150 °C. SO2Cl2 will also decompose when heated to or above 100 °C, about 30 °C above its boiling point. Upon standing, SO2Cl2 decomposes to sulfur dioxide and chlorine, which gives the older samples a slightly yellowish color. SO2Cl2 can be used as a source of chlorine in alkane radical chlorination, initiated chemically (usually by peroxide) or by light:
=== Substrate specificity === Under normal circumstances, caspases recognize tetra-peptide sequences on their substrates and hydrolyze peptide bonds after aspartic acid residues. Caspase 3 and caspase 7 share similar substrate specificity by recognizing tetra-peptide motif Asp-x-x-Asp. The C-terminal Asp is absolutely required while variations at other three positions can be tolerated. Caspase substrate specificity has been widely used in caspase based inhibitor and drug design.
Sources: en.wikipedia.org
=== Religious beliefs === De Duve was brought up as a Roman Catholic. In his later years he tended towards agnosticism, if not strict atheism. However, de Duve believed that "Most biologists, today, tend to see life and mind as cosmic imperatives, written into the very fabric of the universe, rather than as extraordinarily improbable products of chance." "It would be an exaggeration to say I'm not afraid of death", he explicitly said to a Belgian newspaper Le Soir just a month before his death, "but I'm not afraid of what comes after, because I'm not a believer." He strongly supported biological evolution as a fact, and dismissive of creation science and intelligent design, as explicitly stated in one of his last books, Genetics of Original Sin: The Impact of Natural Selection on the Future of Humanity (French original 2009). He was among the seventy-eight Nobel laureates in science to endorse the effort to repeal the Louisiana Science Education Act of 2008.
The possibility of a militarized Japan has also been a continuous concern to the Chinese leadership since the late 1990s. In addition, China's military leadership has been reacting to and learning from the successes and failures of the United States Armed Forces during the Kosovo War, the 2001 invasion of Afghanistan, the 2003 invasion of Iraq, and the Iraqi insurgency. All these lessons inspired China to transform the PLA from a military based on quantity to one based on quality. Chairman Jiang Zemin officially made a "revolution in military affairs" (RMA) part of the official national military strategy in 1993 to modernize the Chinese armed forces. A goal of the RMA is to transform the PLA into a force capable of winning what it calls "local wars under high-tech conditions" rather than a massive, numbers-dominated ground-type war. Chinese military planners call for short decisive campaigns, limited in both their geographic scope and their political goals. In contrast to the past, more attention is given to reconnaissance, mobility, and deep reach. This new vision has shifted resources towards the navy and air force. The PLA is also actively preparing for space warfare and cyber-warfare. In 2002, the PLA began holding military exercises with militaries from other countries. From 2018 to 2023, more than half of these exercises have focused on military training other than war, generally antipiracy, or antiterrorism exercises involving combatting non-state actors.
== In drug discovery == Identification of active sites is crucial in the process of drug discovery. The 3-D structure of the enzyme is analysed to identify active site residues and design drugs which can fit into them. Proteolytic enzymes are targets for some drugs, such as protease inhibitors, which include drugs against AIDS and hypertension. These protease inhibitors bind to an enzyme's active site and block interaction with natural substrates. An important factor in drug design is the strength of binding between the active site and an enzyme inhibitor. If the enzyme found in bacteria is significantly different from the human enzyme then an inhibitor can be designed against that particular bacterium without harming the human enzyme. If one kind of enzyme is only present in one kind of organism, its inhibitor can be used to specifically wipe them out. Active sites can be mapped to aid the design of new drugs such as enzyme inhibitors. This involves the description of the size of an active site and the number and properties of sub-sites, such as details of the binding interaction. Modern database technology called CPASS (Comparison of Protein Active Site Structures) however allows the comparison of active sites in more detail and the finding of structural similarity using software.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.